IMAB - יחס מהיר I-Mab Biopharma Co., Ltd.

I-Mab develops advanced antibodies to combat tumors using platforms that ensure a prolonged drug lifecycle and regular royalty payments. The strategy is based on creating a diversified product portfolio and collaborating with global corporations in the US and China. The price action, where the indicator stands at 23.64, highlights the company's expansion phase through international trials and the launch of current biologics.

The development of innovative oncology drugs and the execution of global trials by I-Mab (IMAB) require massive liquidity expenditures. This metric measures the company's ability to settle short-term obligations using only cash and accounts receivable, completely ignoring inventories. Analyzing the acid-test ratio allows for an assessment of business resilience to market shocks without accounting for slowly realizable assets. The stability of this metric confirms financial autonomy during the implementation of the licensing strategy.